Fig. 11From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsRanibizumab versus control. Serious systemic adverse events comparing ranibizumab with control at 2 years. M-H, Mantel–Haenszel statisticsBack to article page